AngioCode — Vascular-Age Photoplethysmography

AngioCode is a Russian vascular-assessment line (AngioScan / AngioCode-301 / -322) built on photoplethysmography (PPG) — optical pulse-wave sensing — with pulse-wave contour analysis used to estimate “vascular age” and cardiovascular risk. It sits in the Sensing Physics family, and it is one of the atlas's instructive under-study cases: the sensor is real and the method is validated, but the consumer interpretation reaches past what the sensor can support.

The real substrate — a validated sensing method

The substrate to keep is solid. Photoplethysmography with pulse-wave contour analysis is a real, validated physiological measurement: an optical sensor reads the blood-volume pulse, and the shape of that waveform genuinely carries information about the vasculature. This is established sensing physics, not a metaphor — a measurable optical input and a real cardiovascular signal in the contour. That is the half of the record that stands on its own, independent of how the output is then labelled.

Claim vs evidence — why grade C/D

This is the core, and it turns on the gap between a method and an interpretation. The method (PPG, contour analysis) is validated; the broad reading built on top — a consumer “vascular age” number and home cardiovascular risk-stratification — is weakly validated and overreaches the sensor. That earns grade C/D: a real, validated sensing method carrying a consumer diagnostic interpretation that is thinly supported and broader than anything the device is registered for. The single source on record is the Russian device registry, accessible here: Roszdravnadzor registry. No clinical validation study, accuracy statistic, or outcome trial for the broad “vascular age” claim appears in the record, and none is invented here — that absence is exactly why the consumer interpretation lands at C/D rather than higher. The record's own note adds that the registry number, class, and date were corroborated via registry aggregators and should be re-verified at the Roszdravnadzor registry before publication.

Why this tier — and the registered-vs-marketed flag

Keep the axes apart. Plausibility is high for the method (PPG and contour analysis are validated); the grade for the broad consumer claim is only C/D; and the tier follows the claim being made, not the quality of the sensor. This entry carries the flag “narrow registered indication vs broad consumer marketing,” and that flag is the whole story. The registered device, AngioCode-322, is cleared for a narrow purpose; the marketing speaks in the much wider language of “vascular age” and general cardiovascular diagnosis. A real, well-registered narrow indication does not license the broad consumer reading layered over it — that is the precise overreach this entry flags.

Regulatory — narrow Russian registration, one model unregistered

The regulatory facts are specific and worth stating exactly. AngioCode-322 holds Roszdravnadzor РЗН 2013/322, class 2a, registered 15.03.2013 — for a narrow registered indication: noninvasive assessment of endothelial dysfunction and arterial stiffness via a reactive-hyperemia / occlusion test. AngioCode-301 is, by its own leaflet, a household tracker with no registration certificate. US FDA, EU MDR, China NMPA, and Australia TGA status are all not specified in the source. The central regulatory point is the atlas's standing rule: registration is market access, not proof of efficacy — and here the registration covers only the narrow endothelial / stiffness indication, not the broad consumer “vascular age” and risk claims.

History and lineage

The line descends from Russian vascular-assessment instrumentation (the AngioScan / AngioCode family). Within the atlas, its natural pair is Midjourney Medical's full-body ultrasound scanner: the record explicitly frames the two as the same pattern — a real sensing substrate wrapped in a broad interpretation that outruns validation. For how a legitimate measurement gets stretched into a broad diagnostic promise, see the lineage page, and compare the other Sensing Physics entries where instrument and interpretation come apart.

Keep vs set aside

Keep: photoplethysmography with pulse-wave contour analysis as a real, validated measurement, and the narrow registered AngioCode-322 indication — noninvasive assessment of endothelial dysfunction and arterial stiffness via a reactive-hyperemia test. Set aside: the broad consumer “vascular age” / cardiovascular-diagnosis / home risk-stratification marketing, which is weakly validated, broader than the registered indication, and not made true by the registration (grade C/D). The sensor is real; the consumer headline is wider than the sensor.